Skyrizi 600 mg/10mL

Skyrizi 600 mg/10mL injection is a medication used for managing specific inflammatory conditions. This single-dose vial is designed for intravenous administration and is manufactured by AbbVie Inc. in the USA.

Skyrizi 600 mg/10mL injection is primarily used for the treatment of moderate to severe plaque psoriasis, a skin condition characterized by red, itchy, and scaly patches. It may also be prescribed for other inflammatory conditions as determined by a healthcare provider. The active ingredient, risankizumab-rzaa, works by targeting specific proteins involved in the inflammatory process.

Common effects of Skyrizi 600 mg/10mL injection may include reactions at the injection site, such as redness, itching, or swelling. Some individuals might experience fatigue, headache, or upper respiratory infections. These effects vary and are not experienced by everyone.

Skyrizi 600 mg/10mL injection should be handled with care, ensuring proper storage and administration as directed. It is important to inform healthcare providers about any allergies or existing medical conditions before use. This medication should only be administered by a healthcare professional.

Skyrizi 600 mg/10mL injection may interact with other medications, including those that affect the immune system. It is advisable to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements may also influence the effectiveness of this treatment.